"We are very excited about the progress we have made with Array as our partner, since filing our LOXO-101 IND and shifting preclinical resources towards our pipeline," said
Loxo continues to advance LOXO-101, a selective inhibitor of the TRK family of tyrosine kinase receptors. LOXO-101 is currently in a Phase 1 dose-escalation clinical trial, for which initial safety and pharmacokinetic data will be presented in April at the
"For LOXO-101, we will soon turn our focus towards TRK-altered patients, as the dose escalation reaches biologically relevant levels," added
"Loxo has made very exciting and rapid progress with LOXO-101 and its discovery efforts. The company is building a world-class and diverse pipeline, leveraging insights from its
2015 Program Guidance
LOXO-101 is a selective inhibitor of the TRK family of tyrosine kinase receptors.
Initial Phase 1 safety and pharmacokinetic data for LOXO-101 will be presented as a poster at the AACR 2015 Annual Meeting in
Philadelphiain April. The poster will be presented in the Experimental and Molecular Therapeutics session on Tuesday April 21, 2015from 1:00 PM - 5:00 PM ETin poster section 32. Abstracts for AACR 2015 will be published online at 1:00 PM ETon March 18, 2015.
- In the second half of 2015, Loxo will provide an update on its clinical development plans for LOXO-101. Loxo will present future clinical data at a medical meeting if they support proof of concept for LOXO-101 in TRK altered patients.
Active Pipeline Programs
- In addition to the RET, FGFR, and FLT3 programs, Loxo possesses well-vetted candidates for two other programs, not yet disclosed by target name, that are ready for IND-enabling work. We are currently conducting confirmatory pre-IND work for these programs. With supportive data, we could initiate clinical programs for either of these programs in the first half of 2016.
- RET is a tyrosine kinase receptor that binds the glial cell line-derived neurotrophic factor (GDNF) ligand family and contributes to the development of the nervous system and kidneys. Kinase inhibitors with anti-RET activity have demonstrated preliminary anti-tumor activity in experimental trials enrolling lung and thyroid cancer patients with RET fusion proteins and RET mutations. We are designing a highly specific RET inhibitor that optimizes on-target potency for RET fusion proteins, mutations, and clinically-identified resistance mutations.
- The FGFR family of receptors consists of four isoforms with tyrosine kinase domains, numbered one through four (1-4), which play important roles in embryonic development and adult angiogenesis, hormone regulation, and renal function. Fusions, point mutations, and gene amplifications in individual isoforms of the FGFR family have been associated with distinct cancer types in patients, and preliminary anti-tumor activity has been demonstrated in genitourinary, lung, and breast cancers in experimental trials of kinase inhibitors with anti-FGFR activity. We are designing a highly specific FGFR inhibitor that optimizes on-target potency against FGFR. In addition, there may be a therapeutic index advantageand therefore an opportunity for better target coveragewith an isoform-specific FGFR inhibitor, though the structural similarities of FGFR 1-3 create significant challenges for designing such an inhibitor.
- FLT3 is a tyrosine kinase receptor that plays an important role in the development of stem cells and the immune system. In acute myeloid leukemia (AML), so-called internal tandem duplication (ITD) mutations in FLT3 have been associated with poorer outcomes with standard therapies, and predict sensitivity to inhibition with kinase inhibitors with anti-FLT3 activity. Precedent FLT3 inhibitors have taught us much about how leukemia cells acquire resistance to FLT3 directed therapies. We are designing a highly specific FLT3 inhibitor that optimizes on-target potency for the FLT3-ITD mutations and clinically-identified resistance mutations.
- The Company will provide periodic data updates for its discovery pipeline at medical meetings, beginning in the second half of 2015.
Array Collaboration Update
As per its collaboration agreement with
Array BioPharma, Loxo initially held exclusivity for twelve undisclosed targets, excluding TRK. In January 2015, Loxo's exclusivity was reduced to seven targets, and will be further reduced to four targets in January 2016. Loxo has an option for a fifth target, which would trigger a milestone payment to Array.
Conference Call Information
Loxo's management team will host a webcast and conference call discussing the Company's program guidance for 2015 on
A live webcast of the presentation will be available at http://ir.loxooncology.com/. A replay of the webcast will be available shortly after the conclusion of the call and archived on the Company's website for 30 days following the call.
Announcement of 2014 Year-End Financial Earnings
Before market open on
Loxo will be holding its Annual Meeting of Shareholders on
Forward Looking Statements
This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, statements we make regarding our future financial performance, business plans and objectives, partnerships, timing and success of our clinical trials, our ability to obtain regulatory approval, the potential therapeutic benefits and economic value of our lead product candidate or pipeline candidates, potential growth opportunities, financing plans, competitive position, industry environment and potential market opportunities. Further information on potential risk factors that could affect our business and its financial results are detailed in our Quarterly Report on Form 10-Q for the period ended
|Jacob S. Van Naarden|
|Vice President, Corporate Development and Strategy|
|The Trout Group, LLC|
|MacDougall Biomedical Communications|